NIOX Group PLC NIOX

Morningstar Rating
GBX66.80 +0.80 (1.21%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NIOX is trading at a LOCK|Ml#Jzk premium.
Price
£0.66
Fair Value
LOCK|^r%#$%
Uncertainty
LOCK|Bc
1-Star Price
LOCK|czkc>^
5-Star Price
LOCK|scjsX$
Economic Moat
LOCK|pNSH
Capital Allocation
—

Trading Information

Previous Close Price
GBX66.00
Day Range
GBX66.80–68.60
52-Week Range
GBX53.84–76.00
Bid/Ask
GBX0.00 / GBX0.00
Shares Outstanding
420.87M
Market Cap
GBX28.11B
Volume/Avg
180,790 / 626,512

Key Statistics

Price/Earnings (Normalized)
31.62
Price/Sales
5.93
Dividend Yield (Trailing)
2.35%
Dividend Yield (Forward)
2.35%
Dividend Payment Schedule
Jun
Total Yield
2.35%

Company Profile

NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
95

Valuation

Metric
NIOX
Price/Earnings (Normalized)
31.62
Price/Book Value
4.20
Price/Sales
5.93
Price/Cash Flow
18.52
Price/Earnings
NIOX

Financial Strength

Metric
NIOX
Quick Ratio
3.47
Current Ratio
4.60
Interest Coverage
—
Quick Ratio
NIOX

Profitability

Metric
NIOX
Return on Assets (Normalized)
10.04%
Return on Equity (Normalized)
12.38%
Return on Invested Capital (Normalized)
10.63%
Return on Assets
NIOX

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|!TM>&%LOCK|<hw!d$167B
Medtronic PLC
MDT
LOCK|jLNvtsLOCK|d?dZf$111B
Stryker Corp
SYK
LOCK|KV$Z!QJlLOCK|pyN$105B
Boston Scientific Corp
BSX
LOCK|Y$X?%xjLOCK|#X^dT$63B
Edwards Lifesciences Corp
EW
LOCK|Nz>$d!&LOCK|#&<y?$49B
DexCom Inc
DXCM
LOCK|@VQ?#NLLOCK|P!%X$33B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|?M$@&X@LOCK|Wgb$29B
Koninklijke Philips NV ADR
PHG
LOCK|Ch!LOCK|@!>$23B
Steris PLC
STE
LOCK|<?Z!XBYLOCK|!c&&$20B
Zimmer Biomet Holdings Inc
ZBH
LOCK|C^VW$^x#LOCK|d@M$17B

Sponsor Center